Kornimate/medical-research-clean huggingface dataset:
the effect of distractive auditory stimuli (music) on dyspnea and anxiety during exercise in adults with chronic respiratory diseases

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the objective of this study is to look at the effects of distractive auditory stimuli (das) on reducing dyspnea intensity and related anxiety and increasing exercise tolerance. investigators hope that compared to a no-music control condition, that under a music condition participants with copd will (a) demonstrate increased self-paced walk distance and enjoyment; (b) have less dyspnea intensity, (c) experience less dyspnea anxiety; (d) have less fatigue and state anxiety; and (e) higher maximum heart rate. the upbeat music with a tempo of 90 - 100 bpm (an average-to-moderate walking tempo) is expected to have distractive and performance enhancing effects in order to increase tolerance to dyspnea and exercise. the long-term goal of this study is to increase physical activity in adults with copd and rld by promoting dyspnea and fatigue management through use of distractive auditory stimuli in the form of music.

this randomized clinical trial will use a cross-over design. the research will include two within-subject factors, music versus no music and time. each subject will be randomized a single time to receive either music first then no music, or alternatively, no music first then music during two walk tests.

Eligibility criteria:
inclusion criteria: * english speaking * aged 40 years or older, with physician-diagnosed copd * a flow volume loop with a fev1/fvc of \< 0.70 in the past 12 months * medically cleared to participate in nyulmc's pulmonary rehabilitation program. exclusion criteria: * inability to exercise due to musculoskeletalor neurological dysfunction * inability to walk independently (unaided) * deafness or severe hearing impairment requiring hearing aids * mmrc score = 0 ("i only get breathlessness with strenuous exercise").
taking on diabetes to advance you (today)

Conditions: Type 2 Diabetes Mellitus

Summary: the program will consist of diabetes self-management sessions, led by an occupational therapist. the sessions will be held in an individualized format. sessions will focus on diabetes education, self-management education, and education on behaviors and adaptive techniques to optimize participation in daily life with type ii diabetes. as occupational therapists, the investigators and facilitator, aim to focus on establishing healthy habits, roles, and routines for individuals with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * type 2 diabetes * 18 or older * patient at the family medicine center in fort collins exclusion criteria: * reading level below 6th grade * inability to understand written or verbal instructions regarding questionnaires
prospective evaluation in older premature, untreated breast milk and milk processed by the breast-milk bank

Conditions: Infant, Premature, Diseases; Fatty Acid Deficiency

Summary: the purpose of this study is to evaluate the impact of the enteral nutrition type (untreated breast milk, or breast milk processed by the breast-milk bank) on the longitudinal evolution of the total content and plasma profile of essential fatty acids (efa) in a population of premature infants.


Eligibility criteria:
inclusion criteria: * parent's written informed consent * gestational age less than 33 weeks of amenorrhea * hospitalisation in an nicu at the time of inclusion * intended enteral nutrition with breast milk exclusion criteria: * persons not covered by the french social security system * major congenital malformation * participation in other biomedical study protocols * babies that are likely to be transferred to another hospital during the study period

Keywords: breast milk breast-milk bank plasma profile essential fatty acids
do emotions and pain combined affect mechanical pain thresholds and other pain-related variables in individuals with chronic pain?

Conditions: Pain Thresholds; Pain Intensity

Summary: the purpose of this study is to investigate if different emotional states could influence mechanical pain thresholds and other pain - related variables such as pain tolerance, pain intensity and pain - related negative affect in individuals with chronic pain.

participants with chronic pain will be randomized into 4 different groups watching different short video-clips (2.20 min), while at the same time experience short-lasting, experimentally induced pain. the negative emotions group will watch an uncomfortable short video containing violence and blood, the positive emotions group will watch a video containing a stand-up comedy show, the neutral emotions group will watch a video about how to paint a house, and the control group will just wait for 2.20 min, without any instructions about what to think about. pressure pain thresholds, pain tolerance, pain intensity and pain-related negative affect will be measured with an algometer before and after the video-clip combined with experimental pain interventions.

Eligibility criteria:
inclusion criteria: * above 18 years of age * fluent in swedish * persistent chronic pain with duration \> 6 months exclusion criteria: - known neurological disease

Keywords: pressure pain thresholds pain emotions
a randomized study to evaluate the safety, tolerability and antiviral activity of abt-450, abt-333 and abt-072

Conditions: Hepatitis C; HCV; Chronic Hepatitis C Infection; Hepatitis C Genotype 1

Summary: this study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of multiple oral doses of abt-450/ritonavir (r), abt-333 (also known as dasabuvir), or abt-072 in hepatitis c virus (hcv), genotype 1-infected, treatment-naïve adults.

this was a phase 2a, randomized, blinded, placebo-controlled, dose-ranging study in chronically, hepatitis c virus (hcv) genotype 1-infected participants designed to explore the safety, tolerability, pharmacokinetics, antiviral activity, as well as the evolution and persistence to resistance of abt-450/r, abt-333, or abt-072. participants were treated with abt-450/r, abt-333, or abt-072 monotherapy for 3 days, followed by 81 days (12 weeks minus 3 days of monotherapy) of abt-450/r, abt-333, or abt-072 combined with pegylated interferon/ribavirin (pegifn/rbv), followed by 36 weeks of pegifn/rbv alone. participants randomized to an abt-450/r treatment group who achieved rapid virologic response (rvr) and had hcv ribonucleic acid (rna) levels \< 25 iu/ml at all subsequent visits were eligible to stop pegifn/rbv therapy on or after week 24.

Eligibility criteria:
inclusion criteria: * chronic hepatitis c virus (hcv), genotype 1 infection (hcv ribonucleic acid level greater than or equal to 100,000 iu/ml) at screening * liver biopsy within 3 years with histology consistent with hcv-induced liver damage, with no evidence of cirrhosis or liver pathology due to any cause other than chronic hcv * treatment naïve male or female between the ages of 18 and 65 * females must be post-menopausal for more than 2 years or surgically sterile * negative screen for drugs and alcohol * negative hepatitis b surface antigen (hbsag) and anti-human immunodeficiency virus antibodies (anti-hiv ab) * no use of cytochrome p450 3a (cyp3a) and cytochrome p450 2c8 (cyp2c8) enzyme inducers or inhibitors within 1 month of dosing * be in a condition of general good health, as perceived by the investigator, other than hcv infection exclusion criteria: * significant sensitivity to any drug * use of herbal supplements within 2 weeks prior to study drug dosing * history of major depression within 2 years * prior treatment with any investigational or commercially available anti-hcv agents * abnormal laboratory tests
bupivacaine injection of eye muscles to treat strabismus

Conditions: Strabismus; Esotropia; Exotropia; Graves Disease; Ptosis, Eyelid

Summary: this study seeks to determine if bupivacaine injection of eye muscles can make them stronger and stiffer, and thereby correct the position of eyes that are turned in or mis-aligned, a condition generally termed strabismus. it seeks further to find out the different effects of various concentrations or formulations of bupivacaine, and whether addition of botox to other eye muscles can add to the effect of bupivacaine and enhance the correction of strabismus.

patients eligible for inclusion in the study will be age 8 to 95 years and have an eye deviation (strabismus) that is potentially subject to surgical correction. the eye alignment will be measured. the eye muscles may be measured by mri. the eye will be anesthetized by eye drops. one or more eye muscles will be injected with bupivacaine. botox® will be injected into the antagonist muscle in some cases to increase the effect of the bupivacaine. data on the strabismus deviation, any side effects of the drug injection, and the eye muscles as measured by mri, will be recorded at intervals after injection. these data will be compared with the like measurements taken before injection. the primary outcome will be the eye alignment change at 180 days. a secondary outcome will be the change in muscle size, strength, or stiffness. for large strabismus deviations not fully corrected by a first injection, a second injection can be made. follow-up alignment and muscle measurements will be as for the initial injection.

Eligibility criteria:
inclusion criteria: * clinical pattern of strabismus of 5 prism diopters or more exclusion criteria: * active eye infection

Keywords: strabismus diplopia
radiation therapy in treating women undergoing lumpectomy for stage i or stage iia breast cancer

Conditions: Breast Cancer

Summary: rationale: radiation therapy uses high-energy x-rays to kill tumor cells. giving intraoperative radiation therapy after lumpectomy followed by external-beam radiation therapy may kill any tumor cells that remain after surgery. purpose: this phase ii trial is studying the side effects and how well radiation therapy works in treating women undergoing lumpectomy for stage i or stage iia breast cancer.

objectives: * to determine the feasibility and acute patient tolerance of intraoperative electron irradiation (ioert) and hypofractionated external-beam irradiation (hyport) after lumpectomy for patients with stage i-iia breast cancer treated with breast conservation therapy. * to determine the local tumor control and distant tumor control rates for patients with stage i-iia breast cancer treated with breast conservation therapy using ioert and hyport after lumpectomy. * to determine the long-term side effects and cosmetic outcome of ioert to tumor bed and hyport after lumpectomy for patients with stage i-iia breast cancer. outline: patients undergo lumpectomy per standard procedures. patients undergo intraoperative electron irradiation (ioert) to the tumor bed right after completion of lumpectomy with axillary lymph node dissection or sentinel lymph node biopsy. beginning 2-6 weeks after lumpectomy with axillary lymph node dissection/sentinel lymph node sampling and ioert, patients receive hypofractionated external-beam irradiation once daily for 16 days. after completion of study treatment, patients are followed at 3 months, every 6 months for 5 years, and then annually thereafter for 8 years.

Eligibility criteria:
disease characteristics: * histologically confirmed primary invasive breast carcinoma * stage i-iia disease (t1, n0, m0 or t2, n0, m0) * pathologically determined single, discrete, and well-defined primary tumor ≤ 5 cm in diameter * pathologically negative surgical margins * no multicentric disease and/or diffuse malignant appearing microcalcifications * micro-calcifications must be focal * specimen radiograph is required after lumpectomy for tumors associated with malignant appearing calcifications to assure removal of all malignant appearing calcifications * specimen radiograph is optional if the tumor appears as a discrete mass on mammogram * no axillary lymph node involvement * no evidence of metastatic breast cancer * hormone receptor status not specified patient characteristics: * ecog performance status 0-2 * menopausal status not specified * no pre-existing collagen vascular disease except rheumatoid arthritis that does not require immunosuppressive therapy * not pregnant or nursing prior concurrent therapy: * no prior irradiation to the area of planned radiation field * no prior placement of breast prosthesis in the treated breast * concurrent hormonal therapy with external-beam irradiation allowed

Keywords: stage i breast cancer stage ii breast cancer
strep a fia field study, sofia

Conditions: Group A Streptococcus

Summary: to demonstrate the clinical performance of the strep a fia and sofia, using throat swabs collected from symptomatic subjects.


Eligibility criteria:
inclusion criteria: 1. male and female, 3 years of age or older 2. must currently be exhibiting one or more of the symptoms characteristic of pharyngitis to be eligible for inclusion in this study. for example: 1. acute onset of sore throat 2. redness of the posterior pharyngeal wall 3. difficulty/pain on swallowing 4. fever, \> 37.8º c (100ºf) at presentation or within past 24 hours 5. pharyngeal exudate 6. tender cervical lymphadenopathy 7. absence of cough, runny nose or other upper respiratory symptoms.\* 8. other, symptoms specific to strep a not listed above. * must include at least one additional symptom from a-f and cannot be the only criteria used to meet inclusion for enrollment in the study. exclusion criteria: 1. subjects currently under treatment with antibiotics are not to be included in this study. 2. at clinical sites requiring informed consent, unable to understand and consent to participation; for minors this includes parent or legal guardian.

Keywords: strep throat
enhancement of bone regeneration and healing in the extremities by the use of autologous bonofill-ii

Conditions: Bone Fracture

Summary: the purpose of this clinical study is to evaluate the safety and the efficacy of bonofill-ii as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications: 1. long and short bone extra-articular comminuted fracture 2. long and short bones extra and intra articular defect /gap or non-union, incapable of self-regeneration

primary endpoint: safety: to establish that the transplantation of bonofill-ii into bone defect/gap is safe under the following conditions: * no treatment-related appearance of heterotrophic bone ossification * no excessive bone formation at the transplantation sites * no abnormalities in the treated sites efficacy: to establish that the transplantation of bonofill-ii into bone defect/gap is effective under the following conditions: bone continuity rate, measured radiographically by ct at 6 and 12 months.

Eligibility criteria:
inclusion criteria: * long and short bones extra articular comminuted fracture or * long and short bones extra and intra articular defect/gap or non union, incapable of self-regeneration exclusion criteria: * age is under 18 or above 80 * a simple fracture manageable by one definitive treatment * pregnant or lactating women * patients with active infection anywhere in the body except in the injured bone site that is in question and needs osteogenic treatment. * subjects with recorded medical history diseases such as heart diseases, renal failure. * subject treated currently with systemic steroids. * subjects with known autoimmune diseases, such as addison's disease, celiac disease - sprue (gluten-sensitive enteropathy), dermatomyositis, graves disease, hashimoto's thyroiditis, multiple sclerosis, myasthenia gravis, pernicious anemia, reactive arthritis, rheumatoid arthritis, sjogren syndrome, systemic lupus erythematosus. * subjects diagnosed with osteoporosis * subjects that have a known scar healing problem (keloid formation). * subjects treated with bisphosphonate drugs * oncology patients in treatment * subjects who received chemotherapy or radiotherapy treatment in the past * subjects participating in another clinical trial 30 days prior to and during the study period. * drug addicts and psychiatric patients patients incapable of giving consent. * subjects with a known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation. * subjects with any known allergy for local/general anesthesia. * positive serology for either hiv, hepatitis b or hepatitis c. * abnormal clinically significant laboratory test and findings, as per the investigator's judgment.

Keywords: critical gap comminuted fracture extra-articular
the safety and efficacy of intralymphatic immunotherapy in pollen allergic adolescents and young adults with asthma

Conditions: Rhinitis; Asthma; Allergy

Summary: the study evaluates the safety and efficacy of intralymphatic allergen-specific immunotherapy given to adolescents and young adults who are allergic to grass or birch pollen and have mild or moderate asthma. patients will be treated with three intralymphatic injections; 1000 sq-u x3 with 4-5 weeks interval, or placebo with 4-5 weeks interval. the patients receiving treatment will be given a fourth injection one year after the initial injections. the study is conducted in collaboration between professor lars olof cardell (ent), prof gunilla hedlin (pediatrics) and prof marianne van hage (immunology)".

30 patients with seasonal allergic rhinitis due to birch or grass pollen are included. study subjects are randomized to intralymphatic injections with placebo or alk alutard 5-grasses / birch or placebo. the patients receiving treatment will be given a fourth injection one year after the initial injections.

Eligibility criteria:
inclusion criteria: * allergic rhinitis due to grass or birch pollen * mild to moderate asthma with a positive methacholine challenge * accepted and signed informed consent. exclusion criteria: * previously subcutaneous immunotherapy (scit) with total symptom relief. * previously scit but no symptom improvement at all. * sensitizations to house dust mite or furry animals, with ongoing exposure and symptoms. * severe atopic dermatitis. * patients with significant diseases other than allergic rhinitis. a significant disease is defined as a disease which in the opinion of the investigator may either put the patient at risk because of participation in the study or a disease which may influence the results of the study or the patient's ability to participate in the study. * patients with a respiratory tract infection in the past 4 weeks prior to visit 2. * pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception (i.e., oral contraceptives, intrauterine devices, diaphragm, or subdermal implants). * known autoimmune or collagen disease * cardiovascular disease * hepatic disease * known renal insufficiency * cancer * hematologic disease * chronic infectious disease * any medication with a possible side-effect of interfering with the immune response * previous immuno- or chemotherapy * disease or conditions rendering the treatment of anaphylactic reactions difficult (symptomatic coronary heart diseases, severe arterial hypertension and treatment with β-blockers) * major metabolic disease * known or suspected allergy to the study product * obesity with bmi \> 30 since subcutaneous fat makes ultrasound imaging of lymph nodes harder which may risk the correct placement of injection. * patients who, in the opinion of the investigator, abuse alcohol or drugs within 2 years prior to visit 1. * patients who have taken an investigational drug within 1 month or six half lives, whichever is greater, prior to visit 1. * mental incapability of coping with the study * withdrawal of informed consent
observing the changes of fibroblast growth factor 23 in patients of tumor induced osteomalacia

Conditions: Hypophosphatemia

Summary: fibroblast froth factors (fgfs) are humoral factors identified by their ability to stimulate cell proliferation1. they play different roles in the regulation of cell proliferation, differentiation and function. most fgf family members act as paracrine factors. but fgf19(fgf19) subfamily members, including fgf19, 21, and 23, work as endocrine factors to regulate bile acid, carbohydrate and phosphate metabolism2. of these, fgf23 plays an important role in phosphate and bone metabolism3. fgf23 gene encodes 251 amino acids, including a 24-amino acid signal peptide4. the secreted fgf23 is a protein consisted of 227 amino acids. it works by binding to a klotho-fgf receptor 1c (fgf1c) complex5. fgf suppresses the expression of type 2a and 2c sodium-phosphate cotransporters, which mediate phosphate reabsorption in proximal tubules.6 fgf23 decreases 25-hydroxyvitamin d-1α-hydroxylase expression and enhances 25-hydroxyvitamin d-24-hydroxylase expression6. therefore, fgf23 reduces serum 1,25-dihydroxyvitamin d〔1,25(oh)2d〕, which stimulates intestinal calcium and phosphate absorption. fgf23 decreases serum phosphate through the above mechanisms fgf23 over-expression might result in hypophosphatemic rickets and osteomalacia. tumor induced osteomalacia (tio) is a paraneoplastic syndrome usually caused by benign phosphaturic mesenchymal tumors. symptoms are nonspecific, such as general weakness, fatigue, and bone pain. sometimes fracture may occurs. the responsible tumors are sometimes small and difficult to detect. tumors secrete fgf23. fgf23 reduced phosphate reabsorption in the proximal tubules and decrease 1,25(oh)2d levels, which result in hypophosphatemia and then osteomalacia. the investigators would like to observe the changes of fgf23 in patients who receive operation or medical treatment and hope this will benefit future treatment.


Eligibility criteria:
inclusion criteria: * patients with tumor induced osteomalacia. * people without osteomalacia such as healthy people, * people under dialysis, * people with poor nutrition. exclusion criteria: * people younger than 20 years old or older than 85 years old. * people who are pregnant.
the effect of a natural polyphenolic extract from pomegrnate (pomx) on the development of atherosclerosis in diabetic patients

Conditions: Atherosclerosis

Summary: diabetes is a highly atherogenic disease. pomegranate juice has impressive antioxidant properties. it has been proven to decrease oxidant stress and to cause the regression of atherosclerotic plaques in hypercholestrolemic and diabetic patients.furthermore it has been proven to potentiate the biologic activity of the enzyme paraoxonase 1 which is very important in preventing atherosclerosis. the study will try to prove that a polyphenolic extract from pomegranate (pomx) has the same desired effects.


Eligibility criteria:
inclusion criteria: * males * hba1c\>7% * drug therapy given for dm exclusion criteria: * age\<18 * inclusion in another study

Keywords: minors enrollment in another study males hba1c greater than 7 drug therapy for dm